{
    "Clinical Trial ID": "NCT00580333",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cisplatin/Avastin",
        "  Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)",
        "  cisplatin: Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 wks) for four cycles",
        "  bevacizumab: Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three wks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel",
        "  doxorubicin: Postoperative: Given intravenously for four 2-week cycles",
        "  cyclophosphamide: Postoperative: Given intravenously for four two-week cycles",
        "  paclitaxel: Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two week"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  All tumors must be ER-, PR- and HER2-negative",
        "  Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible",
        "  For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes.",
        "  18 years of age or older",
        "  Performance status (PS) of 0 or 1",
        "  Use of an effective means of contraception in subjects of child-bearing potential",
        "  Normal organ function as described in the protocol",
        "Exclusion Criteria:",
        "  Any prior cytotoxic chemotherapy or radiation for the current breast cancer",
        "  HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer",
        "  Life expectancy of less than 12 weeks",
        "  Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study",
        "  Renal dysfunction for which exposure to cisplatin would require dose modifications",
        "  Steroid dependent asthma",
        "  Peripheral neuropathy of any etiology that exceeds grade 1",
        "  Uncontrolled diabetes",
        "  History of malignancy treated without curative intent",
        "  Any other pre-existing medical condition that would represent toxicity in excess of grade 1",
        "  Inadequately controlled hypertension",
        "  Any prior history of hypertensive crisis or hypertensive encephalopathy",
        "  New York Heart Association (NYHA) Grade II or greater congestive hear failure",
        "  History of myocardial infarction or unstable angina within 12 months prior to study enrollment",
        "  Any history of stroke or transient ischemic attack at any time",
        "  Known central nervous system (CNS) disease",
        "  Significant vascular disease",
        "  Symptomatic peripheral vascular disease",
        "  Evidence of bleeding diathesis or coagulopathy",
        "  Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to study enrollment",
        "  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to study enrollment",
        "  Serious, non-healing wound, ulcer or bone fracture",
        "  Proteinuria at screening",
        "  Known hypersensitivity to any component of bevacizumab",
        "  Pregnant or lactating"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer.",
        "  The goal of this measure was to determine the pathologic complete response rate (Miller-Payne (MP) score 5) after preoperative therapy with cisplatin and bevacizumab in ER-, PR-, HER2-negative early breast cancer.",
        "  Time frame: 2 years",
        "Results 1: ",
        "  Arm/Group Title: Cisplatin/Avastin",
        "  Arm/Group Description: Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)",
        "  cisplatin: Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 wks) for four cycles",
        "  bevacizumab: Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three wks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel",
        "  doxorubicin: Postoperative: Given intravenously for four 2-week cycles",
        "  cyclophosphamide: Postoperative: Given intravenously for four two-week cycles",
        "  paclitaxel: Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two week",
        "  Overall Number of Participants Analyzed: 51",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  16        (7 to 29)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/51 (0.00%)"
    ]
}